Is Regneron’s COVID-19 Animal Study Giving More Creedence to Antibody Treatments?
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
All Work
Chris Lange
Take-Two’s Earnings Aren’t Even the Most Exciting Part of Its Report
Take-Two Interactive Software shares saw a bump early Tuesday after it reported mixed fiscal first-quarter financial results late on Monday.
What You Need to Know About Alterity Therapeutics’ Tuesday Move
Alterity Therapeutics stock more than doubled on Tuesday after the company announced new data for its lead drug candidate for the treatment of multiple system atrophy.
Is European Update Overshadowing Amarin’s Lackluster Earnings?
Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.
What ADT’s New Partnership With Google Is All About
Google will invest $450 million in home and small business security firm ADT which will begin offering Google Nest products later this year.
Is It Only Up From Here for Under Armour Stock?
Under Armour stock was crushed on Monday, despite receiving a relatively positive analyst upgrade.
CymaBay Pulls Off Another Win With PBC Liver Disease Study
CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis.
Did Investors Expect Too Much From Clorox Earnings?
Clorox reported better than expected fiscal fourth-quarter financial results before the markets opened on Monday, due largely to stronger consumer demand.
How GW Pharma Is Expanding Its Cannabidiol Seizure Treatment
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
Bristol-Myers, CVS, Disney, Uber and More Major Earnings Coming This Week
This is a preview of a few of the most anticipated quarterly reports due this week, including CVS Health, Uber and Walt Disney.
10 Screaming Earnings Winners That Cannot Be Overlooked
24/7 Wall St. has tracked 10 earnings reports from the last week of July in which the earnings news was very positive and the stock price surged alongside the report.
Keytruda, COVID-19 Hopes Prompt Merck Earnings Beat, Rosy Outlook
When Merck & Co. (NYSE: MRK | MRK Price Prediction) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37…
Is Caterpillar ‘Well Positioned for These Challenging Times’?
Caterpillar reported better than expected quarterly results before the markets opened on Friday, but expectations were rather low.
Are Alphabet’s Earnings Really That Bad?
Search engine behemoth Google reported second-quarter earnings per share of $10.13 and $38.30 billion in revenue. Consensus estimates called for $8.34 in EPS and $37.36 billion in revenue.
Apple’s Stock Split May Not Even Be The Best Part of Its Earnings Report
Apple reported third fiscal quarter earnings per share of $2.58 and $59.7 billion in revenue, compared with consensus estimates that called for $2.04 in EPS and $52.25 billion in revenue. The company also announced…
Why Amazon’s Q2 Is So Shocking
After markets closed on Thursday, e-commerce giant Amazon reported second-quarter earnings per share of $10.30 and $88.91 billion in revenue. The consensus estimates called for $1.46 in EPS and $81.53 billion in revenue.
Facebook Q2 Not Phased By COVID-19 or Advertising Boycott
Social media giant Facebook on Thursday reported $1.80 in earnings per share on $18.69 billion in revenue compared to analysts' consensus estimate calling for $1.39 in EPS and $17.4 billion in revenue.
Johnson & Johnson Takes the Next Big Step in Fighting COVID-19
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Why This Solid Bottom Line Beat Isn’t Holding Up Kraft Heinz
Kraft Heinz reported better than expected second-quarter financial results before the markets opened on Thursday, but shares fell anyway.
Will Edesa Biotech Make It Big as the Newest COVID-19 Stock?
Edesa Biotech joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study. Investors were quick to give this firm the coronavirus bump, more than doubling…